Conference
Abstract B079: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma
Abstract
Abstract
Glioblastoma (GBM) is a uniformly fatal primary brain tumor, characterized by a diverse cellular phenotype and genetic heterogeneity. Despite the use of aggressive cellular multi-modal treatment including surgical resection, radiotherapy and chemotherapy, the outcome of patients with GBM has failed to improve significantly. Numerous studies have implicated CD133+ brain tumor initiating cells (BTICs) as drivers of …
Authors
Vora P; Chokshi C; Qazi M; Venugopal C; Mahendram S; Singh M; Adams J; Bakhshinyan D; London M; Subapanditha M
Volume
4
Pagination
pp. b079-b079
Publisher
American Association for Cancer Research (AACR)
Publication Date
November 1, 2016
DOI
10.1158/2326-6066.imm2016-b079
Conference proceedings
Cancer Immunology Research
Issue
11_Supplement
ISSN
2326-6066